Breaking News, Collaborations & Alliances

Novavax, SK Bioscience Expand Vax Pact

The existing partnership for manufacture of NVX-CoV2373 has been expanded to increase production capacity and supply vaccines to the Korean Government.

Author Image

By: Charlie Sternberg

Associate Editor

Novavax Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, have announced an expanded collaboration and license agreement.   In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and commercialize NVX-CoV2373, Novavax’ COVID-19 vaccine, for sale to the Korean government. Novavax recently reported positive interim efficacy res...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters